Chapter CSB 4

CSB 4.02 CSB 4.02 Definitions. As used in this chapter:

CSB 4.02(1) (1) “Access” means to have the ability to view monitored prescription drug history reports, audit trails, and PDMP data as authorized by s. CSB 4.09.

CSB 4.02(2) (2) “Administer” has the meaning given in s. 961.385 (1) (a), Stats.

CSB 4.02(2m) (2m) “Agent” has the meaning given in s. 961.385 (1) (ab), Stats.

CSB 4.02(3) (3) “Animal” has the meaning given in s. 89.02 (1m), Stats.

CSB 4.02(3m) (3m) “ASAP” means the American Society for Automation in Pharmacy.

CSB 4.02 Note Note: Contact: American Society for Automation in Pharmacy, 492 Norristown Road, Suite 160; Blue Bell, PA 19422; phone: [phone]; fax: [phone]; webpage: http://asapnet.org/index.html.

CSB 4.02(3s) (3s) “Audit trail” means the log that contains information about each time the PDMP system discloses PDMP data, monitored prescription drug history reports, and prescribing metrics reports.

CSB 4.02(4) (4) “Board” means the Controlled Substances Board.

CSB 4.02(4m) (4m) “Business day” has the meaning given in s. 961.385 (1) (ad), Stats.

CSB 4.02(5) (5) “Controlled substance” means a drug, substance, analog, or precursor described in any of the following:

CSB 4.02(5)(a) (a) Schedule I, II, III, IV, or V in the federal controlled substances act, 21 USC 812 (b) (1) to (b) (5) and (c), as changed and updated by 21 CFR 1308.

CSB 4.02(5)(b) (b) Schedule I, II, III, IV, or V in subch. II of ch. 961, Stats., as amended by ch. CSB 2.

CSB 4.02(5k) (5k) “DEA registration number” means the registration number issued to a dispenser or practitioner by the federal department of justice, drug enforcement administration.

CSB 4.02(5m) (5m) “Deliver” or “delivery” has the meaning in s. 961.385 (1) (ae), Stats.

CSB 4.02(6) (6) “Department” means the department of safety and professional services.

CSB 4.02(7) (7) “Dispense” has the meaning given in s. 961.385 (1) (af), Stats.

CSB 4.02(8) (8) “Dispenser” means all of the following:

CSB 4.02(8)(a) (a) A pharmacy.

CSB 4.02 Note Note: A site of remote dispensing authorized under s. 450.062, Stats., is under the supervision of a pharmacy.

CSB 4.02(8)(b) (b) A practitioner who dispenses a monitored prescription drug.

CSB 4.02(9) (9) “Dispenser delegate” means any of the following:

CSB 4.02(9)(a) (a) A managing pharmacist of a pharmacy.

CSB 4.02(9)(b) (b) An agent or employee of a practitioner who has been delegated the task of satisfying the data compilation and submission requirements of ss. CSB 4.04 and 4.05.

CSB 4.02(10) (10) “Dispensing data” means data compiled pursuant to s. CSB 4.04.

CSB 4.02(11) (11) “Drug” has the meaning given in s. 450.01 (10), Stats.

CSB 4.02(11c) (11c) “Healthcare Professional” means a pharmacist, practitioner, registered nurse licensed under s. 441.06, Stats., substance abuse counselor, as defined in s. 440.88 (1) (b), Stats., or individual authorized under s. 457.02 (5m), Stats., to treat alcohol or substance dependency or abuse as a specialty.

CSB 4.02(11g) (11g) “Hospital” has the meaning given in s. 50.33 (2), Stats.

CSB 4.02(11n) (11n) “Law enforcement agency” has the meaning given in s. 165.77 (1) (b), Stats.

CSB 4.02(11r) (11r) “Managing pharmacist” means a pharmacist designated by the pharmacy owner to have responsibility for and direct control of pharmaceutical operations in a pharmacy.

CSB 4.02(11w) (11w) “Medical coordinator” means a person who medically coordinates, directs, supervises, or establishes standard operating procedures for a healthcare professional.

CSB 4.02(12) (12) 

CSB 4.02(12)(a) (a) “Monitored prescription drug” means all of the following:

CSB 4.02(12)(a)1. 1. A controlled substance included in s. 961.385 (1) (ag), Stats.

CSB 4.02(12)(a)2. 2. A drug identified by the board as having a substantial potential for abuse in s. CSB 4.03.

CSB 4.02(12)(b) (b) “Monitored prescription drug” does not mean a controlled substance that by law may be dispensed without a prescription order.

CSB 4.02(12m) (12m) “Monitored prescription drug history report” means all of the following information about a patient, patient address, practitioner, or dispenser compiled by the PDMP system and disclosed as authorized in ss. CSB 4.09 and 4.11:

CSB 4.02(12m)(a) (a) PDMP data.

CSB 4.02(12m)(b) (b) Reports submitted to the program pursuant to s. 961.37, Stats.

CSB 4.02(12m)(c) (c) Information submitted to the program by a healthcare professional.

CSB 4.02(12m)(d) (d) Information from the analytics platform.

CSB 4.02(13) (13) “Patient” has the meaning given in s. 961.385 (1) (aj), Stats.

CSB 4.02(14e) (14e) “PDMP” means the Wisconsin prescription drug monitoring program.

CSB 4.02(15) (15) “PDMP data” means the information compiled and analyzed by the PDMP system from dispensing data submitted to it by dispensers.

CSB 4.02(15b) (15b) “PDMP system” means the web-based application, analytics platform, and all related hardware and software that facilitates the submission of dispensing data and the access to and disclosure of PDMP data, monitored prescription drug history reports, audit trails, and prescribing metrics reports.

CSB 4.02(15e) (15e) “Personally identifiable information” means information that can be associated with a particular person through one or more identifiers or other information or circumstances.

CSB 4.02(15g) (15g) “Pharmacist” has the meaning given in s. 961.385 (1) (aL), Stats. For the purposes of this program, the board recognizes a pharmacist licensed by another state that engages in the practice of pharmacy within the contiguous borders of this state or who practices at a pharmacy licensed under s. 450.065, Stats. as a person authorized to engage in the practice of pharmacy.

CSB 4.02(15r) (15r) “Pharmacist delegate” means an agent of a pharmacist to whom the pharmacist has delegated the task of accessing monitored prescription drug history reports.

CSB 4.02(16) (16) “Pharmacy” has the meaning given in s. 961.385 (1) (an), Stats., including a pharmacy that chooses to solely dispense to animal patients.

CSB 4.02(17) (17) “Practitioner” has the meaning given in s. 961.385 (1) (ar), Stats. For the purposes of this program, the board recognizes a practitioner licensed by another state that engages in the practice of their credentialed profession within the contiguous borders of this state as a person authorized to prescribe and administer drugs.

CSB 4.02(18) (18) “Practitioner delegate” means an agent of a practitioner to whom the practitioner has delegated the task of accessing monitored prescription drug history reports.

CSB 4.02(18m) (18m) “Prescribing metrics report” means all of the following information about a practitioner compiled by the PDMP system and disclosed as authorized in s. CSB 4.09:

CSB 4.02(18m)(a) (a) PDMP data.

CSB 4.02(18m)(b) (b) Audit trails.

CSB 4.02(18m)(c) (c) Reports submitted to the program pursuant to s. 961.37, Stats., about a patient to whom the practitioner has issued a prescription order.

CSB 4.02(18m)(d) (d) Information from the analytics platform.

CSB 4.02(19) (19) “Prescription” has the meaning given in s. 450.01 (19), Stats.

CSB 4.02(20) (20) “Prescription order” has the meaning given in s. 961.385 (1) (b), Stats.

CSB 4.02(21) (21) “Program” means the prescription drug monitoring program established under this chapter.

CSB 4.02(21m) (21m) “Prosecutorial unit” has the meaning given in s. 978.001 (2), Stats.

CSB 4.02(23) (23) “Zero report” means a report that indicates that a dispenser has not dispensed a monitored prescription drug since the previous submission of dispensing data or a zero report.

CSB 4.02 History History: CR 12-009: cr. Register October 2012 No. 682, eff. 1-1-13; correction in (5) (b) made under s. 13.92 (4) (b) 7., Stats., Register October 2012 No. 682; CR 13-065: cr. (3m), (13e), am. (16), (17), r. (22) Register February 2014 No. 698, eff. 3-1-14; (13e) renum. to (14e) under s. 13.92 (4) (b) 1., Stats., Register February 2014 No. 698; correction in (17) made under s. 13.92 (4) (b) 7., Stats., Register February 2014 No. 698; CR 14-003: am. (8) (a), renum. (9) to (9) (intro.) and am., cr. (9) (a), (b), (11g), (11r), am. (15) (intro.), cr. (15g), (15r), am. (17) Register August 2014 No. 704, eff. 9-1-14; correction in (3), (9) (b), (10), (12) (a) 1., 2., (15) (b), (15g), (17), (20) made under s. 13.92 (4) (b) 7., Stats., Register September 2015 No. 717; CR 15-101: am. (4) Register June 2016 No. 726, eff. 7-1-16; EmR1706: emerg. am. (1), (2), cr. (2m), (3s), (4m), (5m), am. (7), cr. (11c), (11n), am. (11r), cr. (11w), am. (12) (a) 1., cr. (12m), am. (13), r. (14), cons. and renum. (15) (intro.) and (a) to (15) and am., r. (15) (b), cr. (15b), (15e), am. (15g), (15r), (16), (17), (18), cr. (18m), (21m), eff. 4-1-17; CR 17-028: am. (1), (2), cr. (2m), (3s), (4m), (5m), am. (7), cr. (11c), (11n), am. (11r), cr. (11w), am. (12) (a) 1., cr. (12m), am. (13), r. (14), cons. and renum. (15) (intro.) and (a) to (15) and am., r. (15) (b), cr. (15b), (15e), am. (15g), (15r), (16), (17), (18), cr. (18m), (21m) Register December 2017 No. 744, eff. 1-1-18; (5k) renumbered from CSB 4.04 (1) (a) under s. 13.92 (4) (b) 1., Stats., Register August 2021 No. 788.

CSB 4.03 CSB 4.03 Drugs that have a substantial potential for abuse. Pursuant to s. 961.385 (1) (ag), Stats., the board has identified all of the following drugs as having a substantial potential for abuse:

CSB 4.03(1) (1) A controlled substance identified in schedule II, III, IV or V in the federal controlled substances act, 21 USC 812 (b) (2) to (b) (5) and (c), as changed and updated by 21 CFR 1308.

CSB 4.03(2) (2) Gabapentin.

CSB 4.03 History History: CR 12-009: cr. Register October 2012 No. 682, eff. 1-1-13; correction in (2) made under s. 13.92 (4) (b) 7., Stats., Register October 2012 No. 682; CR 13-065: am. (intro.) Register February 2014 No. 698, eff. 3-1-14; correction in (intro.) made under s. 13.92 (4) (b) 7., Stats., Register February 2014 No. 698; correction in (intro.) made under s. 13.92 (4) (b) 7., Stats., Register September 2015 No. 717; CR 15-101: r. (3) Register June 2016 No. 726, eff. 7-1-16; EmR1706: emerg. r. (2), eff. 4-1-17; CR 17-028: r. (2) Register December 2017 No. 744, eff. 1-1-18; CR 20-080: cr. (2) Register August 2021 No. 788, eff. 9-1-21.

CSB 4.04 CSB 4.04 Compilation of dispensing data.

CSB 4.04(1) (1) As used in this section, “NDC number” means national drug code number, the universal product identifier used in the U.S. to identify a specific drug product.

CSB 4.04(2) (2) Subject to s. CSB 4.08, a dispenser shall compile dispensing data that contains all of the following information each time the dispenser dispenses a monitored prescription drug:

CSB 4.04(2)(a) (a) The dispenser’s full name.

CSB 4.04(2)(b) (b) The dispenser’s DEA registration number.

CSB 4.04(2)(c) (c) The date dispensed.

CSB 4.04(2)(d) (d) The prescription number.

CSB 4.04(2)(e) (e) The NDC number of the monitored prescription drug.

CSB 4.04(2)(f) (f) The quantity dispensed.

CSB 4.04(2)(g) (g) The estimated number of days of drug therapy.

CSB 4.04(2)(gb) (gb) The drug dosage units.

CSB 4.04(2)(gd) (gd) The partial fill indicator.

CSB 4.04(2)(ge) (ge) The classification code for payment type.

CSB 4.04(2)(gm) (gm) The number of refills authorized by the prescriber.

CSB 4.04(2)(gs) (gs) The refill number of the prescription.

CSB 4.04(2)(h) (h) The practitioner’s full name.

CSB 4.04(2)(i) (i) The practitioner’s DEA registration number.

CSB 4.04(2)(j) (j) The date prescribed.

CSB 4.04(2)(L) (L) The patient’s full name or if the patient is an animal, the animal’s name and the owner’s last name.

CSB 4.04(2)(m) (m) The patient’s address, or if the patient is an animal, patient’s owner’s address, including street address, city, state, and ZIP code.

CSB 4.04(2)(n) (n) The patient’s date of birth, or if the patient is an animal, patient’s owner’s date of birth.

CSB 4.04(2)(o) (o) The patient’s gender.

CSB 4.04(2)(p) (p) The name recorded under s. 450.11 (1b) (bm), Stats.